

A Study of DII235 in Adults With Elevated Lipoprotein(a)

NCT07235046

Status	RECRUITING
Phase	Phase 2
Sponsor	Novartis Pharmaceuticals
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (4)

- Signed informed consent must be obtained prior to participation in the study.
- Male or female participants 18 to 80 years of age (inclusive) at the screening.
- Lp(a) e 150 nmol/L at screening, measured at the central laboratory.
- Participants with evidence of atherosclerotic cardiovascular disease and/or type 2 diabetes mellitus.

Exclusion (5)

- Severe renal dysfunction
- Hepatic dysfunction
- Malignancy within the last 5 years
- Use of investigational medications as defined in the protocol
- History or presence at screening of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the Investigator, or sponsor if consulted, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data

Locations (66 total)

Parkway Medical Center, Birmingham, Alabama, United States
Heart Center Research Llc, Huntsville, Alabama, United States
Cardiology and Medicine Clinic PA, Little Rock, Arkansas, United States
... and 63 more locations